This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for May 20, 2025
by Zacks Equity Research
U.S. stock markets closed higher on Monday after a choppy session.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple
by Zacks Equity Research
Disney, Gilead Sciences, Eaton and Maui Land & Pineapple are included in this Analyst Blog.
Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences, Inc. (GILD) and Eaton Corp. plc (ETN), as well as a micro-cap stock Maui Land & Pineapple Co., Inc. (MLP).
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
by Ekta Bagri
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. We advise investors to remain on the sidelines at current levels.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEY
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
by Zacks Equity Research
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings
by Zacks Equity Research
Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Ekta Bagri
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.